1. Home
  2. USLM vs CELC Comparison

USLM vs CELC Comparison

Compare USLM & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

USLM

United States Lime & Minerals Inc.

HOLD

Current Price

$117.20

Market Cap

3.1B

Sector

Industrials

ML Signal

HOLD

Logo Celcuity Inc.

CELC

Celcuity Inc.

HOLD

Current Price

$103.89

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
USLM
CELC
Founded
1948
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Other Metals and Minerals
Medical Specialities
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.1B
3.1B
IPO Year
1994
2017

Fundamental Metrics

Financial Performance
Metric
USLM
CELC
Price
$117.20
$103.89
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$106.63
AVG Volume (30 Days)
80.4K
537.3K
Earning Date
04-29-2026
03-25-2026
Dividend Yield
0.20%
N/A
EPS Growth
23.22
N/A
EPS
4.67
N/A
Revenue
$144,435,000.00
N/A
Revenue This Year
$13.29
N/A
Revenue Next Year
$8.70
N/A
P/E Ratio
$25.31
N/A
Revenue Growth
N/A
N/A
52 Week Low
$80.47
$7.58
52 Week High
$137.96
$120.32

Technical Indicators

Market Signals
Indicator
USLM
CELC
Relative Strength Index (RSI) 47.82 40.10
Support Level $109.01 $103.65
Resistance Level $129.25 $117.27
Average True Range (ATR) 5.45 5.60
MACD 0.01 -0.71
Stochastic Oscillator 21.09 6.20

Price Performance

Historical Comparison
USLM
CELC

About USLM United States Lime & Minerals Inc.

United States Lime & Minerals Inc is engaged in the business of manufacturing lime and limestone products including PLS, quicklime, hydrated lime and lime slurry. It supplies its products predominantly to the construction (including highway, road, and building contractors), industrial (including paper and glass manufacturers), environmental (including municipal sanitation and water treatment facilities and flue gas treatment processes), metals (including steel producers), oil and gas services, roof shingle manufacturers and agriculture (including poultry and cattle feed producers) industries. The company operates through its Lime and Limestone Operations segment.

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

Share on Social Networks: